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Natural killer (NK) cells are known for their well characterized ability to control viral 
infections and eliminate tumor cells. Through their repertoire of activating and inhibitory 
receptors, NK cells are able to survey different potential target cells for various surface 
markers, such as MHC-I – which signals to the NK cell that the target is healthy – as well 
as stress ligands or viral proteins, which alert the NK cell to the aberrant state of the target 
and initiate a response. According to the “licensing” hypothesis, interactions between 
self-specific MHC-I receptors – Ly49 in mice and KIR in humans – and self-MHC-I mole-
cules during NK cell development is crucial for NK cell functionality. However, there also 
exists a large proportion of NK cells in mice and humans, which lack self-specific MHC-I 
receptors and are consequentially “unlicensed.” While the licensed NK cell subset plays 
a major role in the control of MHC-I-deficient tumors, this review will go on to highlight 
the important role of the unlicensed NK cell subset in the control of MHC-I-expressing 
tumors, as well as in viral control. Unlike the licensed NK cells, unlicensed NK cells seem 
to benefit from the lack of self-specific inhibitory receptors, which could otherwise be 
exploited by some aberrant cells for immunoevasion by upregulating the expression of 
ligands or mimic ligands for these receptors.
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iNTRODUCTiON
Natural killer (NK) cells are part of the innate immune system and were originally identified due to 
their unique ability to kill tumor cells without prior sensitization, which greatly differed from the 
defined functions of other major lymphocyte subsets (1, 2). The ability of an NK cell to recognize 
tumor or virus-infected cells is due to the expression of various activating and inhibitory receptors 
on its cell surface; such receptors include Ly49, CD94/NKG2, and NKp46, among others (3). While 
NK cell deficiencies are rare – possibly highlighting the necessity of NK cells in immunity – the few 
documented cases of NK cell deficiencies further support their important role. Individuals who 
exhibit reduced NK cell numbers, cytotoxicity, and/or cytokine production are characteristically 
more susceptible to certain viral infections (4–12).
Target cells can express ligands that bind to a variety of activating and inhibitory receptors on 
NK cells; it is this interplay between inhibitory and activating signals, which determines the NK 
cell response to the target (3). In addition, upon recognition of pathogen-associated molecular pat-
terns, sentinels of the immune system, such as dendritic cells and macrophages, secrete a range of 
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inflammatory cytokines in order to recruit and activate NK cells. 
Macrophages and dendritic cells are known producers of IL-2, 
IL-15, IL-18, and IL-21, all of which stimulate production of both 
type I and II IFNs by NK cells, as well as direct cytotoxicity of NK 
cells (13–17).
Members of the Ly49 receptor family, the murine functional 
homolog of the human killer-cell Ig-like receptor (KIR) family, can 
be either activating or inhibiting and interacting with class I major 
histocompatibility complex (MHC-I) molecules (18). Almost all 
adult nucleated cells constitutively express MHC-I molecules 
on their surface (19, 20). Both NK and CD8+ T cells depend on 
MHC-I recognition for their function. While the engagement of 
T cell receptors by MHC-I molecules is required for CD8+ T cell 
activation, the opposite is true for NK cells (21, 22). According 
to the “missing-self ” hypothesis, NK cells preferentially target 
cells lacking MHC-I expression, which is recognized by self Ly49 
receptors (23, 24). MHC-I expression on the target cell surface 
acts as a health marker for NK cells, signaling to the NK cell to 
spare the target. Conversely, aberrant cells often downregulate the 
surface expression of MHC-I to avoid detection and killing by 
cytotoxic T cells, but become a target for NK cells (25, 26).
The classical characterization of an NK cell is its ability to 
recognize and eliminate cells, which have decreased surface 
expression levels of MHC-I, a common phenomenon in cancer 
cells (2, 27, 28). Varied expression levels of human MHC-I  –
human leukocyte antigen (HLA)  –  on cells shows an inverse 
correlation with their susceptibility to killing by NK cells: variants 
with decreased levels of HLA were more susceptible to NK cell 
killing than the parental cell line, and accordingly, variants with 
higher levels of HLA benefited from protection from NK cells 
compared to the original cell line (29). While other inhibitory 
receptors, such as NKG2A, have been shown to play a role in NK 
cell licensing as well (30), the focus of our review will be on the 
dual role of the Ly49 family receptors on NK cells during target 
cell recognition and immune evasion.
MHC-i-MeDiATeD NK CeLL  
eDUCATiON/LiCeNSiNG
Natural killer cell functionality depends on the presence of 
self-MHC-I molecules as proposed by the “licensing” hypoth-
esis, in which a self-specific Ly49 receptor must interact with 
self-MHC-I in order for the NK cell to become functional (30, 
31). Consequently, NK cells from B2m−/− mice, in which MHC-I 
expression is abrogated, exhibit a diminished ability to kill 
MHC-I-deficient target cells that are normally readily killed by 
NK cells from WT mice, and exhibit defective cytokine produc-
tion (28, 32). Similarly, our studies have demonstrated that the 
NK cells from Ly49-deficient mice are unlicensed and show 
impaired recognition of MHC-I-deficient target cells (33). NK 
cell responsiveness has also been shown to be proportional to the 
number of self-MHC-I-specific inhibitory receptors they express 
(34, 35). NK cells that express a higher number of self-MHC-I-
specific Ly49 receptors are more responsive to stimuli than those 
that express fewer of these receptors. Human NK cells undergo a 
similar licensing process, which requires the interaction of HLA 
and KIR (36, 37). NK cells expressing self-MHC-I-specific KIRs 
exhibited a more robust responsiveness and cytokine production 
than self-KIR-negative NK cells.
While the mechanics of NK cell licensing are still unclear, 
whether it be via the arming, disarming, or rheostat model, or 
through cis interactions with self-MHC-I [as previously reviewed 
in Ref. (38)], the process has been shown to be an ongoing 
and fluid process, wherein an environmental change can alter 
the licensed state of even fully mature NK cells (34, 39–41). 
Contrary to the original school of thought that NK cell educa-
tion occurs during NK cell development in the bone marrow, 
when unlicensed mature NK cells from MHC-I-deficient mice 
were adoptively transferred into WT mice, their function was 
restored showing that mature NK cell can also acquire licensing 
through the interaction of their inhibitory Ly49 receptors with 
the host MHC-I molecules (30, 31, 39, 40). Although licens-
ing is important for NK cells to acquire effector functions, the 
unlicensed NK cells appear to respond effectively against target 
cells under specific conditions, such as when the target cells 
express high levels of MHC-I to evade NK detection by inter-
acting with the inhibitory Ly49 receptors. This ability to detect 
MHC-I-expressing tumors and viruses may be the reason why 
up to 50% of NK cells are unlicensed with respect to self-Ly49 
expression, but are still maintained in immune-competent mice 
(31, 42).
CANCeR iMMUNOSURveiLLANCe  
BY NK CeLLS
The importance of the immune system in tumor control is high-
lighted by the increased cancer risk in immune-compromised 
individuals. Those with human immunodeficiency virus (HIV) 
infection, including individuals who have progressed to acquired 
immunodeficiency syndrome (AIDS), are at notably greater 
risk of developing lung cancer independent of smoking (43). 
Immunosuppressed renal transplant patients have increased 
incidence of skin cancer over the general population (44). Those 
having undergone heart transplants are particularly at increased 
risk for non-Hodgkin’s lymphoma, oral, and lung cancers (45). 
Moreover, in human cross-sectional studies, the presence of 
tumor infiltrating lymphocytes is a strong predictor of posi-
tive patient outcome (46), indicating a correlation between the 
immune system and cancer protection or recovery.
In support of the importance of NK cells in cancer immunity, 
NK-compromised beige mice  –  a model for human Chediak–
Higashi syndrome – exhibit defective cytotoxic activity against 
tumor cells, and are more susceptible to spontaneous fatal tumor 
development, possibly due to ineffective immunosurveillance 
(47, 48). Chediak–Higashi syndrome is caused by a homozygous 
or compound heterozygous mutation in the lysosomal traffick-
ing regulator gene. Affected individuals present with a host of 
immunodeficiency disorders such as granular anomalies in their 
lymphocytes, defective chemotactic and bactericidal activity 
of their neutrophils, defective NK cell function, and defective 
peptide loading and antigen presentation (49–52). Antibody-
mediated depletion of NK cells prior to tumor cell injection in 
various mouse strains results in prolonged tumor survival, as 
well as an increased number of artificial lung metastases and 
FiGURe 1 | NK cell response to MHC-i-deficient tumors. Licensed NK cell recognition MHC-I-deficient tumors through “missing-self” due to a lack of MHC-I 
expression on the tumor cell (A), as well as through “induced-self” via stress ligands, which are recognized by activating receptors on NK cells (B). Unlicensed NK cells are 
unable to recognize MHC-I-deficient tumors through “missing-self” (C), however, are still functional upon activating receptor–ligand interaction for “induced-self” recognition 
(D). NK cell response “−” represents no activation, and “+” represents activation. In the case of (C), +/− represents that the response of the NK cell, whether it is activated 
or not, also depends upon other immune cells, receptor–ligand interactions, and cytokines in the tumor microenvironment, which are not depicted in the figure for brevity.
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spontaneous metastases (53). In humans, NK cells comprise up to 
15% of the blood lymphocytes (54). In a clinical setting, low NK 
cell activity in cancer-diagnosed individuals has been associated 
with poor prognosis, and those with advanced stage cancer often 
possess minimally cytotoxic NK cells (55). High cytotoxic activity 
of peripheral blood NK cells is correlated with up to 10% reduced 
incidence of cancer (56). As well, in a clinical case of childhood-
onset Hodgkin’s lymphoma, this individual was observed to have 
non-functional NK cells (57).
ReCOGNiTiON OF MHC-i-DeFiCieNT 
TUMOR CeLLS BY LiCeNSeD NK CeLLS
Tumors have developed multiple mechanisms for evading host 
immune recognition. One well-documented escape mechanism, 
the downregulation of MHC-I expression, is effective against 
T cells, but renders the tumor more susceptible to NK cells. Reduced 
expression levels of MHC-I has been documented in bladder, 
breast, cervical, colorectal, and ovarian human cancers (58–63).
The classic tumor model, in which missing-self was first dis-
covered retrospectively, also helps to highlight the importance of 
the MHC-I status of the target cell (23). Mutagenesis of RBL-5, 
a Rauscher virus-induced leukemia, led to the derivation of the 
MHC-I-deficient RMA-S and MHC-I-expressing RMA cell lines 
(23). The difference in MHC-I expression levels of these two 
cell lines leads to differential recognition by NK cells (23). The 
RMA-S induced flank tumors are much better controlled com-
pared to the accelerated growth of the RMA tumors (23). With 
the use of B2m−/− mutant mice, it has been shown that a MHC-I 
deficiency renders the NK cells defective at killing traditionally 
well recognized MHC-I-deficient NK tumor cell line targets (32).
Our group has shown that mice lacking Ly49-mediated NK 
licensing also exhibit reduced activity against MHC-I-deficient 
tumor cells both in vitro and in vivo (Figure 1) (33). In the in vivo 
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rejection assays spanning up to 18 h, these mice exhibited reduced 
capacity at eliminating the MHC-I-deficient variants of RMA 
and C1498 compared to wild-type mice (33). Ly49-mediated 
NK cell education plays a major role in NK cell-mediated cancer 
immunosurveillance with tumor cell-induced flank tumors, 
experimental tumor metastases, methylcholanthrene-induced 
sarcoma, and spontaneous B cell lymphoma, with observations 
of increased and earlier onset tumor incidence in each model 
(64). Interestingly, the tumors, which developed in the mice with 
reduced levels of licensed NK cells, exhibited MHC-I-directed 
tumor immunoediting, wherein levels of both H-2Kb and H-2Db 
were reduced, possibly as a mechanism of escape from cytotoxic 
T cells in an environment where evasion from NK cells is no 
longer a priority for survival due to their unlicensed nature (64).
iNDUCeD-SeLF ReCOGNiTiON OF 
TUMOR CeLLS BY UNLiCeNSeD  
NK CeLLS
While the self-specific inhibitory Ly49 receptors have been shown 
to be the mediators of NK cell licensing required for effective 
missing-self recognition (65), blockade of these receptors also 
helps to elicit a stronger NK cell response. Antibody-mediated 
blockade of self-specific Ly49 receptors improved B2m−/− bone 
marrow allograft success similar to results seen with complete 
NK cell depletion; suggesting the importance of the inhibitory 
self-specific Ly49C/I subset in the effector functions of NK cells 
(66). This study shows successful grafting of MHC-I-deficient 
bone marrow cells in WT mice when Ly49C/I+ NK cells are 
depleted, thus providing evidence for missing self-recognition of 
MHC-I-deficient bone marrow cells by licensed NK cells.
Treatment of NK cells with monoclonal blocking antibody to 
Ly49C/I led to inhibited in  vitro growth of MHC-I-expressing 
C1498, a murine leukemia cell line, and EL4, a T cell lymphoma 
cell line (65). In vivo antibody blockade prior to leukemia induc-
tion with C1498 led to increased survival (65). Considering eve-
rything we know about NK cell education and the importance of 
the Ly49C/I subset in licensing, in this case, the inhibitory nature 
of these receptors takes precedence over their educating role. 
However, one thing of note is the MHC-I status of the tumor cell 
lines utilized, with both lines expressing moderate to high levels 
of MHC-I, suggesting that missing-self recognition by licensed 
NK cell subsets is not a key requirement in this case. Self MHC-
licensed NK cells are much less efficient than unlicensed NK cells 
at responding to the MHC class I-expressing target RMA cells 
(67). The requirement for licensed NK cells is not as imperative 
in the event that the tumor cells express MHC-I, since these 
cells would not traditionally be recognized through missing-self. 
Various cancer cells, which maintain expression of MHC-I on 
their cell surface, while escaping immune recognition through a 
missing-self response can also dampen NK cell activity through 
engagement of inhibitory KIRs (68–70). Antibody-mediated 
blockade of all KIR2D receptors elicits a heightened NK cell 
response with respect to cell cytotoxicity and has proven its 
efficacy in stage 1 clinical trials against acute myeloid leukemia 
and multiple myeloma (69–71).
In some instances, it appears that the unlicensed NK cells are 
more efficient at eliminating MHC-I-expressing aberrant cells 
(Figure 2). Unlicensed human NK cells, which lack inhibitory 
self-KIR expression, are more effective at killing neuroblastoma 
cells through antibody-dependent cell-mediated cytotoxicity 
(ADCC), following treatment with an antibody, which targets 
the disialoganglioside surface antigen GD2 on tumor cells (72). 
The activated NK cells recognize MHC-I on the cell surface as 
a health marker, thus sparing the MHC-I-expressing neuroblas-
toma cells and concurrently selecting for the MHC-I-expressing 
subset. MHC-I-expressing tumor cells can inhibit licensed NK 
cells through the engagement of inhibitory KIRs. Unlicensed 
NK cells, on the other hand, are not inhibited and are better 
mediators of neuroblastoma cell killing via ADCC, which is 
particularly relevant in the absence of tumor-expressed NK 
activating ligands (72). Therefore, unlicensed NK cells appear 
to be the better mediators of an anti-tumor response when the 
tumor cells express ligands for self-specific inhibitory NK cell 
receptors.
Natural killer cells can also kill certain virus-infected and 
tumor cells despite their expression of MHC-I, as explained by 
the “induced-self ” model (73–75). The licensed status of the NK 
cell, in this case, does not wholly dictate its response. Several 
studies have shown that unlicensed NK cells can recognize aber-
rant cells through the recognition of activating ligands, similar 
to licensed NK cells (Figures 1 and 2). The NKG2D activating 
receptor plays a major role in the control of both lymphoid and 
non-lymphoid cancers; loss of this receptor leads to increased 
susceptibility of oncogene-driven cancer development (76). 
Expression of Rae1, the ligand for the activating NKG2D recep-
tor, on RMA cells elicits a strong in vivo rejection response by 
unlicensed NK cells in Ly49-deficient mice (33). In vitro killing of 
splenocytes from Rae1ɛ transgenic mice is comparable between 
licensed and unlicensed NK cells, indicating no effect of licensing 
in this model (33). Additionally, in  vitro and in  vivo killing of 
Rae1β-expressing RMA-S cells is comparable between NK cells 
from wild-type mice and unlicensed NK cells from B2m−/− and 
Ly49-deficient mice, suggesting that other signals, such as those 
from activating receptors, are able to compensate for the hypore-
sponsiveness of unlicensed NK cells to the loss of MHC-I expres-
sion (33, 64). As well, stimulation with the double-stranded RNA 
viral mimic, polyinosinic:polycytidylic acid (poly I:C), induces 
a strong immune response in the otherwise hyporesponsive 
Ly49-deficient mice against MHC-I-deficient B16 F10 tumor 
cells. Prior treatment with poly I:C improves tumor rejection, 
reducing the number of pulmonary metastases in Ly49-deficient 
mice to wild-type levels (64). While the unlicensed NK cells are 
hyporesponsive in an Ly49-dependent manner, NK activation 
can be achieved through other means, which can bypass the 
hyporesponsiveness of these cells.
NK CeLL-MeDiATeD ReCOGNiTiON OF 
viRUS-iNFeCTeD CeLLS
The importance of NK cells in an immune response against a 
pathogen challenge can be seen in various clinical case studies 
FiGURe 2 | NK control of MHC-i-sufficient tumors. Licensed NK cells do not elicit a response against MHC-I-expressing tumor cells, since the presence of 
MHC-I is recognized as a health marker. Tumor cells have evolved various immune evasion mechanisms, such as in this case, to make them appear as a healthy 
“normal” cell to NK cells by presenting MHC-I; however, this may render them susceptible still to cytotoxic T cells (A). The response to both activating and inhibitory 
signals, such as expression of both MHC-I and an activating stress ligand is dependent on a balance of activating and inhibitory signals, which will determine the 
response (B). Unlicensed NK cells do not respond strongly to tumor cells, which express MHC-I (C); however, a stronger response is elicited if the tumor cell 
expresses stress ligands recognized by the activating receptor (D). In the case of unlicensed NK cells, the response is stronger since the activating signal is not 
dampened by inhibitory signals via inhibitory Ly49–MHC-I interaction as in the licensed NK cells. NK cell response “–” represents no activation, and “+” represents 
activation.
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of individuals lacking functional NK cells, leading to recurrent, 
life-threatening infections by otherwise  non-consequential 
pathogens (4, 77). In humans, NK cells have been shown to play 
a seminal role in the control of viruses from the herpesvirus, 
poxvirus, and papillomavirus families (4, 77). Murine studies 
have further established the importance of NK cells in protection 
against vaccinia, hepatitis, and cytomegalovirus infections (78). 
In one study, anti-asialo GM1 antibody-mediated depletion of NK 
cells followed by viral infection lead to increased viral titer and 
interferon (IFN) production, as well as increased viral-associated 
hepatitis and liver  damage (78).
Viruses have evolved mechanisms to evade recognition by 
immune cells. The MHC-I antigen presentation machinery 
appears to be a major target for immunoevasion by viruses. 
Murine cytomegalovirus (MCMV) gene products, such as m06, 
m152, and m04, have the ability to alter MHC-I function (79–82). 
While m06 and m152 gene products interfere with the expres-
sion of assembled MHC-I molecules on the cell surface, m04 
gene product does not interfere with cell surface expression, but 
rather prevents MHC-I recognition by T cell receptors (79–82). 
These strategies as well as the expression of an MHC-I mimic 
(described below) prevent recognition of infected cells by T cells 
FiGURe 3 | Unlicensed NK cells dominate responses to MCMv infection in MCMv-resistant mouse strains. In MCMV-resistant mouse strain, NK cells 
activation occurs when the activating Ly49H receptor is engaged by m157 protein on the infected cells. Simultaneous engagement of inhibitory Ly49 receptors by 
MHC-I molecules can inhibit activation of licensed NK cells (A). In unlicensed NK cells, the interaction of Ly49H and m157 induces a strong activating response due 
to the lack of self-MHC-I-specific inhibitory Ly49 receptors on these cells (B). NK cell response “−” represents no activation, and “+” represents activation.
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and at the same time maintain sufficient expression of ligands for 
inhibitory Ly49 receptors to prevent “missing-self ” recognition 
by NK cells. Similarly, an increased binding of inhibitory KIR 
by MHC-I ligands on infected cells is reported during influenza 
virus infection (83, 84). In these studies, a redistribution of 
MHC-I molecules on the infected cells was proposed to allow 
better recognition by the inhibitory KIR and subsequent NK cell 
inhibition (84). Infection of a human pulmonary epithelial cell 
line by influenza virus was also shown to activate p53 and cause 
MHC-I upregulation on the surface of infected cells (85).
Viruses have been shown to also utilize other mechanisms, 
such as mimicry of host proteins on their cell surface, to evade 
host immune recognition. Often these viral mimics engage 
inhibitory receptors on immune cells to cause inhibition of 
immune responses. A classical example of this is the product 
of MCMV m157 gene, a viral MHC-I-like protein expressed on 
the surface of infected cells (86, 87). While similar to MHC-I in 
structure, expression of the viral mimic is independent of the 
host’s MHC-I antigen processing machinery (88). Engagement 
of inhibitory Ly49 receptors by m157 molecules on the surface 
of infected cells causes NK cell inhibition in MCMV-susceptible 
mouse strains (Figure 3) (89). Leukocyte Ig-like receptor 1, also 
known as ILT2, is a cell surface receptor expressed on human 
immune cell subsets including T and NK cells, and is capable 
of binding classical MHC-I and HLA-G (90). A mechanism 
of immune evasion by human cytomegalovirus involves the 
expression a glycoprotein human homolog of MHC-I, UL18, 
which can inhibit NK cell function by binding to its ILT2 
receptor (91, 92).
Nevertheless, NK cells are able to recognize virus-infected 
cells through the engagement of their activating receptors. 
Activating receptors on NK cells are thought to have arisen as a 
result of selective pressure exerted by continuous pathogen chal-
lenge. Following Epstein–Barr infection, increased expression of 
a MHC-I ligand, which interacts with the activating KIR2DS1, 
is detected on the cells surface (93). In MCMV-resistant mouse 
strains, such as C57BL/6 (B6), the activating Ly49H receptor is 
able to recognize the MCMV m157 glycoprotein (86, 87). The 
presence of the activating Ly49H receptor in the Ly49 receptor 
repertoire of B6 mice confers resistance from MCMV infection. 
In contrast, strains, which lack genes encoding for the activating 
Ly49H, such as 129 and BALB/c, or the genetically manipulated 
Ly49H-deficient B6, are highly susceptible to MCMV infection 
(86, 87, 94). In the 129 mouse strain, m157 binds the inhibitory 
Ly49I receptor (86). Sequence variants of m157 are known to also 
interact with the inhibitory Ly49C receptor from B6 mice, which 
could inhibit NK cell activation. However, since most Ly49H+ NK 
cells do not express Ly49C, MCMV clearance is not disrupted in 
B6 mice (95, 96). Similarly, the activating Ly49P receptor confers 
resistance in MA/My mice to MCMV infection through the 
recognition of MCMV m04 protein in association with H-2Dk 
MHC-I haplotype (97, 98). In both cases, viral gene products 
aimed at evading immune recognition have become the target 
for activating Ly49 receptors.
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iS NK CeLL LiCeNSiNG ALwAYS 
ReQUiReD FOR THe ReCOGNiTiON  
OF viRUS-iNFeCTeD CeLLS?
The fact that the same inhibitory receptors, which are exploited 
by viruses to evade immune recognition, are also involved in NK 
cell licensing raises the question of whether NK cell licensing is 
always required for the recognition of virus-infected cells. As it 
appears, licensed NK cells, bearing inhibitory Ly49 receptors, 
are at a disadvantage during certain virus infections. It has been 
shown during MCMV infection that the NK-mediated response 
is dominated by the unlicensed (Ly49C/I−) NK cell subset (67). 
While the antibody used to deplete the licensed NK cells, 5E6, 
is expected to deplete both Ly49C and Ly49I, there is also evi-
dence that 5E6 is only capable of recognizing Ly49I on NK cells 
(99, 100).
In contrast to licensed NK cells, which are the primary media-
tors of an anti-tumor response through missing-self recognition, 
it is the unlicensed cell subset, which confers protection from 
MCMV infection. Selective depletion of the Ly49C/I+ licensed 
NK cell subset rendered minimal viral titer increase, while deple-
tion of Ly49C/I− unlicenced NK cells led to significant viral titer 
increase in the infected mice. Moreover, adoptive transfer of the 
Ly49H+ Ly49C/I− NK cell subset into neonatal mice was sufficient 
to protect them against an MCMV infection, and was more effec-
tive than the Ly49H+ Ly49C/I+ NK cell subset. The interaction 
between Ly49C/I and its ligand limits the ability of licensed 
NK cells to control the infection. These findings indicated that 
unlicensed NK cells are responsive and play a major role in an 
immune response during a viral infection, the activity of unli-
censed NK cells could be due to the pro-inflammatory cytokine 
environment of viral infection, which is known to enhance NK 
cell function. As a further confirmation, the classical unlicensed 
NK cell model – B2m−/− mice – which possess only unlicensed 
NK cells due to their lack of MHC-I surface expression, was 
better able to control MCMV infection than their wild-type 
counterparts (67). NK cell depletion in B2m−/− during MCMV 
infection leads to enhanced virus titer in the salivary gland 
(80). Our group has also shown that Ly49-deficient and B2m−/− 
mice, which possess unlicensed NK cells, fare better following 
influenza infection than their wild-type counterparts in an NK 
cell-dependent manner (101). B2m−/− and Ly49-deficient mice 
treated with NK cell-depleting monoclonal antibody, as well as 
perforin-deficient Ly49-deficient mice, are more susceptible to 
influenza virus infection, demonstrating that the improved sur-
vival of these mice is due do the functional activity of unlicensed 
NK cells. The Ly49-deficient mice exhibit reduced viral titer and 
lung pathology. Our study also provides evidence for influenza 
virus infection-driven immune evasion. Following influenza 
virus infection, upregulation of MHC-I is observed on pulmo-
nary epithelial cells, possibly as a mechanism to evade detection 
by licensed NK cells. This provides Ly49-deficient mice with an 
advantage since their unlicensed NK cells will not be affected 
by the increased levels of MHC-I, which would traditionally be 
recognized by members of the Ly49 receptor family leading to NK 
cell inhibition. Moreover, blockade of the interaction between 
Ly49:MHC-I rendered licensed NK cells in wild-type mice better 
at controlling influenza virus infection. It is suggested that the 
unlicensed NK cells are better effectors in viral control due to 
their ability to surpass inhibition mediated by MHC-I or MHC-
I-like viral ligands expressed on the surface of infected cells.
In a hematopoietic stem cell transplantation (HSCT) mouse 
model for NK cell licensing, depletion of licensed NK cells 
resulted in higher viral titers in the liver of MCMV-infected mice 
at early time points but not at later time points after infection 
(102). In the same study, the licensed NK cells also expanded and 
produced IFNγ upon infection but were suppressed by regula-
tory T (Treg) cells and TGF-β (102). It was proposed that the 
licensed NK cells mount a strong early response against MCMV 
infection, but become inhibited or exhausted. The unlicensed NK 
cells, on the other hand, show a strong late response due to the 
presence of activation stimuli and the absence of inhibition from 
the inhibitory Ly49:MHC-I binding. This is also corroborated by 
results showing that prior activation by stimuli, such as poly I:C, 
results in an efficient anti-virus and anti-tumor response by the 
unlicensed NK cells (64, 66, 102).
Epidemiological human studies have shown that HIV-infected 
individuals who have KIR3DS1, an activating NK cell receptor, 
and its ligand, HLA-B Bw4-80I, exhibit slow progression to AIDS, 
compared to other HIV-infected individuals (103). In support of 
this finding, an in vitro study has shown that NK cells derived 
from individuals with the KIR3DS1/HLA-B Bw4-80I compound 
genotype were able to mediate inhibition of HIV-1 replication 
in a contact-dependent manner (104). Interestingly, early after 
HIV infection, the frequencies of the activating KIR3DS1+ and 
the inhibitory KIR3DL1+ NK cells are specifically increased in 
patients with acute HIV-1 infection in the presence of HLA-B 
Bw480I. Unfortunately, this expansion is not associated with 
reduction in HIV levels in the blood. Engagement of the inhibi-
tory KIR3DL1 receptor on these NK cells with its ligand on the 
target cells could result in the inhibition of NK cell cytotoxicity 
toward the HIV-infected cells, explaining the maintained level 
of HIV in those patients in comparison to KIR3DL1-deficient 
patients (105). Similarly, studies have shown that CD56− CD16+ 
NK cells, which are greatly expanded in HIV-viremic individuals, 
have impaired function. Characterization of this NK cell subset 
revealed that the expression of inhibitory KIR2DL2 and KIR2DL3 
receptors were high on these cells, which would explain their 
defective lytic capability toward HIV-infected cells (106). Taken 
together, these reports indicate that HIV-infected cells may aug-
ment NK cell inhibition through interactions between inhibitory 
KIR and HLA receptors.
Therefore, under circumstances where inhibitory Ly49 recep-
tors are engaged strongly by MHC-I or viral mimic ligands on the 
infected cells, NK cells that lack inhibitory receptors for MHC-I 
seem to exhibit better effector functions. This may also explain 
why a large proportion of unlicenced NK cells, which do not 
express receptors for self-MHC-I, are maintained in both mice 
and humans. In mice, up to half of the NK cells are “unlicensed” 
with respect to self-Ly49 expression (31, 42). In human studies, 
almost 25% of CD56dim and over 60% of CD56bright NK cells 
do not express KIR, as assessed by their negative staining for 
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KIR2DL1, KIR2DS1, KIR2DL2, KIR2DL3, KIR2DS2, KIR3DL1, 
and KIR2DS4 (107).
CONCLUSiON
These non-conventional observations possibly underlie a differ-
ent approach to understanding NK cell function dependent on 
its licensed or unlicensed status. The licensed status of the cell 
is of biological importance during rejection of MHC-I-deficient 
cancer cells, MHC-mismatched bone marrow transplants, and 
other target cells which exhibit MHC-I downregulation. Various 
studies suggest that licensed NK cells excel at tumor cell rec-
ognition and, while still controversial, the unlicensed NK cells 
preferentially protect from viral infections. The roles of these NK 
cell subsets may not be so clearly defined as either preferential to 
viral or cancer control, but may be due to more nuances of the 
disease. Viral infection induces robust cytokine secretion, which 
may reactivate unlicensed NK cells to respond to the infection. 
Additionally, the status of NK cell control may not be dependent 
on the cells being licensed or unlicensed, as it has been shown that 
activation can happen in the absence of licensing through other 
means such as through engagement of activating receptors such 
as NKG2D, ADCC, or through immunostimulants such as poly 
I:C. Rather, NK recognition may be dependent on the character-
istics of the aberrant cell, including its MHC-I expression levels 
and the microenvironment where they are encountered. The 
role for unlicensed NK cells in the control of cancers and virally 
infected cells, which have mediated upregulation of MHC-I helps 
to explain why the unlicensed NK cell subset is still present in 
modern day mice and humans, and has not been evolutionarily 
selected against.
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